+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab



Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab



American Journal of Gastroenterology 97(2): 499-500




(PDF emailed within 0-6 h: $19.90)

Accession: 035980822

Download citation: RISBibTeXText

PMID: 11866306

DOI: 10.1111/j.1572-0241.2002.05514.x


Related references

Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH. Zeitschrift für Gastroenterologie 42(10): 1256-1263, 2004

Treatment of recurrent Crohn's uveitis with infliximab. American Journal of Gastroenterology 103(8): 2150-2151, 2008

Fulminant acute hepatitis B after infliximab treatment in Crohn's disease. La Tunisie Medicale 92(5): 349-350, 2015

Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. American Journal of Gastroenterology 95(11): 3334-3336, 2000

An epidemiology of research to avoid dissipation of resources of the Italian national health service. Epidemiologia E Prevenzione 42(1): 96-97, 2018

A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease. Korean Journal of Gastroenterology 63(5): 308-312, 2016

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China. Biomed Research International 2016: 8648307, 2017

Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiological Research 52(1): 89-93, 2003

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. Journal of Crohn's and Colitis 9(3): 238-245, 2015

Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis. Internal Medicine 54(12): 1553-1557, 2015

Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. Danish Medical Journal 60(4): B4616, 2014

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. Plos One 10(12): E0144900, 2016

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Internal Medicine Journal 31(3): 146-150, 2001

Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial. Inflammatory Bowel Diseases 21(9): 2114-2122, 2016

Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. American Journal of Gastroenterology 100(7): 1438-1439, 2005